Table 1 Study characteristics (n = 248)
Variable | Number (%) |
|---|---|
Publication year | |
2018 | 54 (21.8) |
2019 | 49 (19.8) |
2020 | 61 (24.6) |
2021 | 42 (16.9) |
2022 | 42 (16.9) |
Most prevalent journals | |
Critical Care | 10 (4.0) |
BMC Anesthesiology | 9 (3.6) |
Journal of Parenteral and Enteral Nutrition | 7 (2.8) |
Journal of Cardiothoracic and Vascular Anesthesia | 7 (2.8) |
Pilot and Feasibility Studies | 6 (2.4) |
Impact factor [median (Q1, Q3)] | 2.6 (1.8, 3.8) |
Country income level | |
High | 181 (73.0) |
Upper middle | 38 (15.3) |
Lower middle | 29 (11.7) |
WHO region | |
Americas | 83 (33.5) |
Eastern Mediterranean | 15 (6.0) |
Europe | 77 (31.0) |
South-East Asia | 20 (8.1) |
Western Pacific | 52 (21.0) |
Mixed | 1 (0.4) |
Source of fundinga | |
Government | 59 (23.8) |
Private | 101 (40.7) |
Industry | 32 (12.9) |
Non-funded | 55 (22.2) |
Not reported | 41 (16.5) |
Field of anesthesiologya | |
Acute pain management | 33 (13.3) |
Advanced obstetric anesthesia | 7 (2.8) |
Advanced pain medicine | 5 (2.0) |
Cardiac anesthesia | 29 (11.7) |
Critical emergency medicine | 9 (3.6) |
Intensive care | 136 (54.8) |
Neurosurgical anesthesia | 2 (0.8) |
Palliative care | 2 (0.8) |
Pediatric anesthesia | 14 (5.6) |
Surgery | 107 (43.2) |
Other | 5 (2.0) |
Type of intervention | |
Pharmacological | 105 (42.3) |
Non-pharmacological | 143 (57.7) |
Trial durationb, months [median (Q1, Q3)] | 11 (6, 20) |
Trial design | |
Parallel | 202 (81.4) |
Crossover | 15 (6.0) |
Multi-arm | 29 (11.7) |
Factorial | 2 (0.8) |